In summary, our findings indicate that CDK1 is a previously unappreciated targetable vulnerability in oxaliplatin resistance, and CDK1 inhibitor combined with oxaliplatin represents a promising strategy in the treatment of patients with oxaliplatin‐resistant CRC. The gene discussed is CDK1; the disease is colorectal carcinoma.